LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE:PBYI), a development stage
biopharmaceutical company, announced the initiation of its Phase III
clinical trial of the Company's lead drug candidate PB272 (neratinib) in
patients with HER2-positive metastatic breast cancer who have failed two
or more prior treatments (third-line disease).
The Phase III trial will be a randomized trial of PB272 plus Xeloda
versus Tykerb plus Xeloda in patients with third-more...